Anti-Diabetes Drugs - GCC | Statista Market Forecast

The Anti-Diabetes Drugs market in the GCC region is expected to witness a significant revenue growth in the coming years.
According to projections, the revenue in this market is anticipated to reach US$700.60m by 2024.
Furthermore, it is estimated that the market will continue to expand at a compound annual growth rate (CAGR 2024-2029) of 7.31%, resulting in a market volume of US$997.10m by 2029.
When compared to other countries globally, United States is expected to generate the highest revenue in the Anti-Diabetes Drugs market.
In 2024, the revenue United States is projected to reach US$37.84bn.
This highlights the significant market potential and demand for anti-diabetic drugs United States.
The demand for anti-diabetes drugs is growing rapidly in the GCC, driven by the high prevalence of diabetes in the region.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in GCC has been experiencing steady growth over the past few years.

Customer preferences: Customers in GCC countries have shown a preference for oral anti-diabetes drugs over other forms of treatment. This is due to the ease of use and convenience that oral drugs provide. Additionally, customers are becoming increasingly health-conscious and are seeking out drugs with fewer side effects.

Trends in the market: One trend in the Anti-Diabetes Drugs market in GCC is the increasing use of combination therapies. This involves using multiple drugs to treat diabetes, which has been shown to be more effective than using a single drug. Another trend is the rising popularity of generic drugs, which are more affordable than brand-name drugs. This has led to increased competition in the market and has made anti-diabetes drugs more accessible to a wider range of customers.

Local special circumstances: The high prevalence of diabetes in GCC countries has led to a growing demand for anti-diabetes drugs. Additionally, the region has a high rate of obesity, which is a major risk factor for developing diabetes. This has led to increased awareness of the importance of managing diabetes and has contributed to the growth of the anti-diabetes drugs market.

Underlying macroeconomic factors: The GCC region has a growing population and a high level of economic development, which has contributed to the growth of the anti-diabetes drugs market. Additionally, the region has a strong healthcare infrastructure, which has made it easier for customers to access anti-diabetes drugs. However, the region also faces challenges such as a lack of healthcare funding and a shortage of healthcare professionals, which could impact the growth of the anti-diabetes drugs market in the future.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.